Advertisement
UK markets closed

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     

  • AIM

    755.28
    +2.16 (+0.29%)
     

  • GBP/EUR

    1.1679
    +0.0022 (+0.19%)
     

  • GBP/USD

    1.2491
    -0.0020 (-0.16%)
     

  • Bitcoin GBP

    51,124.00
    -966.81 (-1.86%)
     

  • CMC Crypto 200

    1,383.71
    -12.82 (-0.92%)
     

  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     

  • DOW

    38,239.66
    +153.86 (+0.40%)
     

  • CRUDE OIL

    83.66
    +0.09 (+0.11%)
     

  • GOLD FUTURES

    2,349.60
    +7.10 (+0.30%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

AstraZeneca's drug sales weighed on by flagging Crestor

Reuters - UK Focus

LONDON, Nov 10 (Reuters) - Competition from multiple generic versions of its cholesterol fighter Crestor hit AstraZeneca (NYSE: AZN - news) 's third-quarter sales but the drugmaker mitigated the damage with income from disposals and good growth in new products.

Revenue declined 4 percent $5.7 billion but core earnings per share (EPS), which exclude some items, rose 28 percent to $1.32, the British group said on Thursday.

Industry analysts had on average forecast quarterly revenue of $5.90 billion and earnings of 97 cents a share, according to Thomson Reuters (Dusseldorf: TOC.DU - news) .

For the full year AstraZeneca reiterated its forecast of a low to mid single-digit percentage decline in both revenue and core earnings at constant exchange rates.

(Reporting by Ben Hirschler; Editing by Greg Mahlich)